Online first
Short communication
Published online: 2024-05-20
High-risk PCI facilitated by levosimendan infusion and Impella CP support in ACS cohort-pilot study
Pubmed: 38845424
Abstract
Not available
References
- Perera D, Clayton T, O'Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022; 387(15): 1351–1360.
- Pietrasik A, Gąsecka A, Pawłowski T, et al. Multicenter registry of Impella-assisted high-risk percutaneous coronary interventions and cardiogenic shock in Poland (IMPELLA-PL). Kardiol Pol. 2023; 81(11): 1103–1112.
- Vetrovec GW, Anderson M, Schreiber T, et al. The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. Am Heart J. 2018; 199: 115–121.
- Chieffo A, Ancona MB, Burzotta F, et al. Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in ITaly: the IMP-IT registry. EuroIntervention. 2020; 15(15): e1343–e1350.
- Tycińska A, Grygier M, Biegus J, et al. Mechanical circulatory support. An expert opinion of the Association of Intensive Cardiac Care and the Association of Cardiovascular Interventions of the Polish Cardiac Society. Kardiol Pol. 2021; 79(12): 1399–1410.
- Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. J Cardiovasc Pharmacol. 2020; 76(1): 4–22.
- Husebye T, Eritsland J, Müller C, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail. 2013; 15(5): 565–572.
- Rola P, Włodarczak A, Jastrzębski A, et al. Impella protected percutaneous coronary intervention on the last remaining highly calcified coronary artery facilitated by shockwave intravascular lithotripsy and levosimendan infusion. Kardiol Pol. 2021; 79(10): 1145–1146.
- Atkinson TM, Ohman EM, O'Neill WW, et al. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention: An interventional perspective. JACC Cardiovasc Interv. 2016; 9(9): 871–883.
- Garcia-Garcia HM, McFadden EP, Farb A, et al. Academic Research Consortium. Standardized end point definitions for coronary intervention trials: The academic research consortium-2 consensus document. Eur Heart J. 2018; 39(23): 2192–2207.
- Baumann S, Werner N, Al-Rashid F, et al. Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: Results from the German Impella® registry. Clin Res Cardiol. 2018; 107(8): 653–657.
- Januszek R, Pawlik A, Rzeszutko Ł, et al. Clinical outcomes in patients undergoing complex, high-risk percutaneous coronary intervention and haemodynamic support with intra-aortic balloon versus Impella pump: Real-life single-centre preliminary results. Kardiol Pol. 2022; 80(12): 1224–1231.
- Wallace TW, Berger JS, Wang A, et al. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2009; 103(3): 355–360.
- Książczyk M, Gruchała M, Stopczyńska I, et al. A favorable alliance between repetitive use of levosimendan and advanced heart failure: Polish two-centered inpatient perspective in need of validation. Kardiol Pol. 2023; 81(3): 287–289.
- Long YX, Cui DY, Kuang X, et al. Effect of levosimendan on renal function in background of left ventricular dysfunction: A meta-analysis of randomized trials. Expert Opin Drug Saf. 2021; 20(11): 1411–1420.
